AUTHORS
Muhammad Yousuf, Shraddha Patel2, Shivani Udyawar3, Abiola Bolarinwa4, Aysel Bayraktar5, Merry Nakhleh6, Momna Warraich7, Kaaren Reichard, MD8, David Viswanatha, MD9, Rong He, MD10, Rhett Ketterling, MD11, Patricia Greipp, DO12, Linda Baughn, PhD13, Xinjie Xu, PhD, FACMG14, Animesh Pardanani, PhD, MBBS15, Naseema Gangat, MBBS16, Ayalew Tefferi, MD17, Cinthya J. Zepeda Mendoza18
AFFILIATIONS
1 Mayo Clinic, Rochester, MN, United States
2 Mayo Clinic, Rochester, MN, United States
3 Mayo Clinic, Rochester, MN, United States
4 Mayo Clinic, Rochester, MN, United States
5 Mayo Clinic, Rochester, MN, United States
6 Mayo Clinic, Rochester, MN, United States
7 Mayo Clinic, Rochester, MN, United States
8 Mayo Clinic, Rochester, MN, United States
9 Mayo Clinic, Rochester, MN, United States
10 Mayo Clinic, Rochester, MN, United States
11 Mayo Clinic, Rochester, MN, United States
12 Mayo Clinic, Rochester, MN, United States
13 Mayo Clinic, Rochester, MN, United States
14 Mayo Clinic, Rochester, MN, United States
15 Mayo Clinic, Rochester, MN, United States
16 Mayo Clinic, Rochester, MN, United States
17 Mayo Clinic, Rochester, MN, United States
18 Mayo Clinic, Rochester, MN, United States
ABSTRACT
Background:
Ring chromosomes (RCs) are structural cytogenetic abnormalities arising from end-to-end chromosomal fusion following double-strand DNA breaks, with attendant loss of gene-rich material and genomic instability. We leveraged the Mayo Clinic cytogenetics repository to conduct a comprehensive study of RCs in myeloid neoplasms (MNs), with the aim of establishing prevalence, cytogenetic context, genotype correlates, corresponding morphologic diagnoses, and associated overall survival (OS) estimates.
Methods:
Pathologic diagnoses were assigned according to the International Consensus Classification (ICC) criteria (Blood 2022. 140:1200). Cytogenetic results were reported according to the International System for Human Cytogenetic Nomenclature (ISCN 2020). CLIA-approved NGS testing was used to curate mutational data. For OS analysis, patients were censored at the time of allogeneic stem cell transplantation (ASCT).
Results:
A Mayo Clinic enterprise-wide cytogenetic database search (2000–2026) identified RCs in 3,139 (3.3%) of 95,411 cases of abnormal bone marrow or peripheral blood cytogenetic studies, with higher detection rates in internally-referred (726/14,165; 5.1%) vs. externally-referred (2,416/81,246; 3.0%) specimens (p<0.01). In the most recent decade (2015-2026), Mayo Clinic internally referred abnormal karyotypes numbered 8,944, including 3,847 patients with MNs. Of the latter, 426 (11%; all NGS annotated) harbored RCs and constituted the current study population (median age 70 years; males 65%). Specific diagnoses included myelodysplastic syndromes (MDS; N=215; 51%), acute myeloid leukemia (AML; N=159; 37%), myeloproliferative neoplasms (MPNs; N=26; 6%), pure erythroid leukemia (PEL; N=16; 4%), and chronic myelomonocytic leukemia (CMML; N=10; 2%). RCs were detected at the time of diagnosis of MNs in 389 cases (91%; de novo 65%, therapy-related 26%), while the remaining 36 (9%) were detected post-MN therapy, in the setting of residual disease.
The chromosomal origin of the RC was not identified in the majority of the MNs study cohort (N=375/426; 88%) but, when identified, involved most frequently chromosome 7, r(7) (N=34; 8%); the remaining identified cases included chromosomes 2, 3, 5, 6, 8, 11, 12, 18, 21 and Y (N=17; 4%). Fluorescence in situ hybridization (FISH) technique was employed in some cases to determine the origin of RCs, with limited yield. RCs occurred as a single cytogenetic abnormality in only 5 (1%) cases, whereas the remaining were accompanied by one other abnormality (N=30; 7%) or were part of a complex karyotype (CK; N=390; 92%). Among NGS-annotated cases, the most frequent mutations seen at the time of RC detection included TP53 (72%; multi-hit 44%), DNMT3A (12%), ASXL1 (7%) and U2AF1 (4%).
Comparative analyses revealed significant associations for r(7) with chronic (CMML/MPN/MDS) vs. acute (PEL/AML) MNs (30%/12%/11% vs. 0%/3%) [p<0.01], isolated RC with CMML vs. other MNs (20% vs. 0-1%; p<0.01), and therapy-related setting with PEL (100%) vs. MDS (39%), MPN (8%), or CMML (10%) [p<0.01]. Genotype associations included TP53 mutations with PEL (100%), MDS (75%), or AML (72%) vs. MPN (41%) or CMML (22%) [p<0.01], and ASXL1 with MPN (47%) [p<0.01]. At a median follow-up of 4.5 months, 359 (84%) deaths and 86 (21%) ASCTs were documented. Median OS was dismal in PEL at 2 months and incrementally better in AML (4 months), MDS (6 months), CMML (10 months), and MPN (17 months; p<0.01). Blast transformation was more frequent in CMML (50%) compared to MDS and MPNs (15% each; p<0.01).
Comparison of patients with RCs in the context of CK vs. non-CK disclosed alignment of the former with TP53 mutation (p<0.01) and the latter with r(7) and mutations involving TET2, ASXL1, EZH2, KRAS, RUNX1, PTPN11, GATA2, CEBPA, and NPM1 (p≤0.02 in all instances). Consistently, OS was worse in the presence of CK in the setting of both AML (p=0.02) and MDS (p<0.01).
Conclusion: RCs are infrequent but not rare (?3%) in routine karyotype analysis and their origin is often not readily identified. In MN, RCs are often seen in the context of CK and in association with TP53 mutations, which may largely account for the observed poor survival estimates across disease subtypes. Accurate assessment of disease-specific prognostic relevance requires larger studies, which might not be feasible considering low incidences of informative cases.
DISCLOSURES
Muhammad Yousuf: No relevant conflicts of interest to declare.